

Pharmaceutical Distributors Respond to the COVID-19 Pandemic



America's pharmaceutical distributors connect 180,000 healthcare providers and pharmacies with 1,300 drug manufacturers across the country. Through these partnerships, pharmaceutical distributors are going above and beyond to maintain access to vital health products for the more than 180 million patients who regularly take prescription medicines during the COVID-19 (coronavirus) pandemic.

Responding to COVID-19



As the logistics experts of healthcare, distributors are taking proactive steps to ensure that pharmacies, hospitals, providers and patients have access to the medicines and supplies they need during this time of uncertainty. The federal government has designated distributors as critical infrastructure and the industry is responding to the pandemic by:

- Continuing around the clock operations to fulfill orders and make deliveries to customers;
- Working closely with federal and state health officials to facilitate information sharing and coordination;
- Communicating in real time with their manufacturer partners to quickly learn of any impact on the supply chain;
- Providing timely and accurate information to their customers about product availability;
- Collaborating with supply chain partners to help ensure a continuous supply of products and minimize service disruptions for patients who rely on pharmacies, hospitals, long-term care or other healthcare facilities to fill and dispense their prescriptions;
- Engaging with Healthcare Ready, an industry collaboration that leverages strong relationships with government, nonprofit and medical supply chains to build and enhance the resiliency of communities; and,
- Maintaining active business continuity plans in the event of disruptions to operations.

Supporting Supply Chain Partners



During this challenging time, distributors are supporting the healthcare facilities and providers on the frontline of the pandemic, as well as manufacturing partners who are working around-the-clock to produce existing products while developing the critical treatments for this public health crisis. Distributors are prepared to leverage their distribution networks once a COVID-19 treatment is developed to ensure rapid patient access.

Collaborating with the Public and Private Sector



HDA and its members stand ready to collaborate with the White House, Congress, governors and state officials across the country, as well as other public and private healthcare leaders to ensure the safety, health and well-being of the American public at this critical juncture.

For more information visit www.HDA.org/covid19